Developer docs
API playgroundTry for free, no card

Search company profiles

WoundGenex

Full company profile

uuid0024ug2

Namestring
WoundGenex
Legal namestring
WoundGenex
Websiteurl
woundgenex.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

WoundGenex is a privately held, Tampa, Florida-based healthcare services company founded in 2014 that provides revenue cycle management (RCM), clinical documentation improvement (CDI), and credentialing and enrollment services to wound care providers in the United States. The company is built around wound care specialty billing, with a particular focus on Medicare cellular and tissue-based product (CTP) reimbursement, skin substitute billing, LCD compliance, and denial management. Its technology platform is an online client portal that enables electronic insurance verification requests, product inventory tracking, clinical team communication, and electronic CTP logs; there is no public API, SDK, or AI/ML product capability disclosed in the company's own material.

WoundGenex monetizes through multi-year, quote-based enterprise contracts with healthcare facilities across wound care centers, physician practices, hospitals, surgical centers, nursing homes, and mobile wound care providers, with specialty service lines for podiatry, vascular surgery, and dermatology. In addition to professional services revenue, the company distributes advanced wound care products — including MiMedx placental allografts (EPIFIX, EPICORD, EpiEffect, Celera, Epixpress, RegenKit Wound Gel), UltraMIST therapy, and MolecuLight wound imaging devices — through the Premier Graft Program, a deferred-payment model underpinned by an exclusive distribution partnership with MiMedx Group (Nasdaq: MDXG) established in March 2022.

The company has no disclosed outside funding and appears to be founder-owned, with Thomas Smith serving as President and Co-founder and Tom listed as CEO. In September 2025, WoundGenex formalized a strategic alliance with Shoreline Medical Administration to bundle its RCM platform with Medicare clawback protection backed by an A-rated insurance carrier. The company's go-to-market is direct enterprise field sales supplemented by content marketing on wound care reimbursement policy, credentialing best practices, and regulatory updates published through its corporate website.

Short descriptiontext

WoundGenex provides revenue cycle management, clinical documentation improvement, credentialing, and deferred-payment wound care product distribution to US wound care, podiatry, vascular, and dermatology providers, with specialty focus on Medicare CTP and skin substitute reimbursement.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTampa, United States
HQ citystring
Tampa
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wound care billing, revenue cycle management, clinical documentation improvement, healthcare credentialing services, wound care distribution
Industry3 codes
PRIMARYHLAKACAN
Wound Care & Ulcer Management
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLADAJAM
Wound Care & Limb Preservation Centers (Post-Acute)
Healthcare & Life Sciences/Elder Care & Long-Term Care/Rehabilitation & Post-Acute Care Centers (Inpatient/Outpatient)
SIC code1 code
  • Services-Health Services8000
Product category
Healthcare Revenue Cycle Management
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Revenue Cycle Management Services
TypeProfessional Services
Description

Full-spectrum RCM solutions including claims processing, insurance verification, accounts receivable management, denial management, and billing optimization for wound care practices

woundgenex.com
2Clinical Documentation Improvement Services
TypeProfessional Services
Description

CDI services focused on accurate and comprehensive clinical documentation to support proper coding, billing, and compliance

woundgenex.com
3Credentialing & Enrollment Services
TypeProfessional Services
Description

Provider enrollment and credentialing management, contract negotiations, and ongoing credential maintenance

woundgenex.com
4Premier Graft Program
TypeManaged Services
Description

Deferred payment model for wound care grafting products where providers pay only after receiving reimbursement, facilitated through group purchasing power with no upfront cost

woundgenex.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details1 tier
1Custom enterprise pricing for healthcare facilities
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing tailored to facility size, specialty mix, and service requirements. No public pricing available.

woundgenex.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

WoundGenex provides full-spectrum wound care revenue cycle management (RCM), clinical documentation improvement (CDI), credentialing and enrollment services, and program management for healthcare providers across the United States. The company also distributes advanced wound care products including MiMedx placental allografts (EPIFIX, Epicord, EpiEffect, Celera, Epixpress, RegenKit Wound Gel), UltraMIST therapy, and MolecuLight wound imaging devices, primarily through its Premier Graft Program with a deferred payment model.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduces claim denials through accurate coding and documentation
+2 more records
Product overview1 text field

WoundGenex is a wound care revenue cycle management and practice management solutions company founded in 2014, serving wound care centers, physician practices, nursing homes, and hospitals. The company operates as a distributor of advanced wound care products including MiMedx placental allografts (Epifix, Epicord, EpiEffect, Celera, Epixpress, RegenKit Wound Gel), UltraMIST therapy, and MolecuLight wound imaging devices (MolecuLightDX, MolecuLight i:X). WoundGenex's core offerings include Revenue Cycle Management, Clinical Documentation Improvement, Credentialing & Enrollment, and the Premier Graft Program—a deferred payment model enabling providers to access products with payment due only after reimbursement. The company also provides an online client portal for insurance verification, inventory tracking, and documentation management.

Product and service13 records
1Revenue Cycle Management (RCM)
CategoryRevenue Cycle Management Services
Description

Full-spectrum Revenue Cycle Management solutions for wound care practices including eligibility verification, claims submission, insurance correspondence, denial management, accounts receivable management, and reimbursement optimization.

2Clinical Documentation Improvement (CDI)
CategoryClinical Documentation Services
Description

Clinical Documentation Improvement services ensuring accurate, comprehensive, and compliant clinical documentation in wound care including assessment, analysis, education, training, and technology integration to support proper coding, billing, and audit readiness.

3Credentialing & Enrollment
CategoryCredentialing Services
Description

Provider enrollment and credentialing management services including contract negotiations, ongoing credential maintenance, and ensuring accurate, compliant, and timely submissions to payers.

4Premier Graft Program
CategoryWound Care Product Distribution Program
Description

Deferred payment program providing healthcare providers access to advanced wound care grafting products (MiMedx allografts) with payment due only after reimbursement is realized, leveraging group purchasing power with no upfront cost to providers.

5EPIFIX (distributed product)
CategoryAdvanced Wound Care Allograft
Description

MiMedx advanced wound care placental allograft product used for treating diabetic foot ulcers and other chronic wounds, covered by 100% of national commercial payors.

6EPICORD (distributed product)
CategoryAdvanced Wound Care Allograft
Description

MiMedx placental allograft product used for wound care applications.

7EpiEffect (distributed product)
CategoryAdvanced Wound Care Allograft
Description

Tri-layer human placental allograft that promotes healing in acute and chronic wounds, combining benefits of human placental tissue with practical application advantages.

8CELERA (distributed product)
CategoryAdvanced Wound Care Allograft
Description

MiMedx advanced wound care product for advanced wound management.

9EPIXPRESS (distributed product)
CategoryAdvanced Wound Care Allograft
Description

MiMedx wound care placental allograft product for advanced wound management.

10RegenKit Wound Gel (distributed product)
CategoryWound Care Topical Product
Description

Wound care gel product for advanced wound management applications.

11UltraMIST (distributed product)
CategoryWound Care Therapy System
Description

Wound care therapy system used in advanced wound treatment.

12MolecuLightDX (distributed product)
CategoryWound Imaging Device
Description

Wound imaging device for advanced wound care diagnostics.

13MolecuLight i:X (distributed product)
CategoryWound Imaging Device
Description

Wound imaging device for wound care visualization and assessment.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-02
Description

Strategic alliance to deliver bundled revenue cycle solutions with Clawback Protection Guarantee. Shoreline provides rigorous documentation oversight, LCD compliance expertise, and AI validation tools, while WoundGenex provides industry-leading RCM services. The partnership safeguards providers against costly Medicare clawbacks backed by an A-rated insurance carrier.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-03-16
Description

Exclusive partnership to launch the Premier Graft Program providing MiMedx advanced wound care products (EPIFIX, Epicord, EpiEffect, Celera, Epixpress, RegenKit Wound Gel) through WoundGenex's group purchasing model. Providers access products with no upfront payment until reimbursement is realized.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

nThrive provides end-to-end revenue cycle management, analytics, and consulting to acute-care and specialty providers. Comparable to WoundGenex as a direct RCM competitor with broader scale and a multi-specialty portfolio.

TypeBroad incumbent
Description

Waystar is a healthcare payments and RCM technology platform serving 1M+ providers. Comparable as a tech-enabled claims and revenue cycle vendor, though more horizontal than WoundGenex's wound-care-specialized offering.

TypeDirect peer
Description

Wound Care Advantage offers consulting, program management, and operational support specifically to wound care centers and hyperbaric programs. Closest direct peer given the same wound-care vertical focus on practice optimization and reimbursement.

TypeOthers
Description

MiMedx is WoundGenex's exclusive Premier Graft Program partner, manufacturer of placental allograft skin substitutes (Epifix, Epicord, EpiEffect, Celera, Epixpress). Relevant as the upstream product vendor rather than a direct competitor.

TypeBroad incumbent
Description

Parallon delivers revenue cycle, credentialing, and workforce solutions to hospitals and physician practices. Comparable as a scaled RCM/credentialing services peer operating across multiple healthcare segments.

TypeBroad incumbent
Description

Conifer provides revenue cycle management, patient engagement, and value-based care services for hospitals, health systems, and physician practices. Comparable as an enterprise-scale RCM incumbent with broad service breadth.

TypeDirect peer
Description

Aviacode / CorroHealth offers technology-enabled medical coding and CDI services, including specialty-specific coding for wound care, radiology, and other niches. Comparable as a coding and CDI services peer to WoundGenex's specialty documentation business.

TypeDirect peer
Description

Zotec Partners delivers specialized revenue cycle management and billing services for physician practices, including niche medical specialties. Comparable as a specialty-focused RCM/BPO peer competing for specialty-practice billing engagements.

TypeBroad incumbent
Description

Experian Health provides patient access, RCM, and identity-management solutions to hospitals and physician practices. Comparable as a large-scale healthcare revenue cycle technology vendor, broader than wound-care-specialized offerings.

TypeDirect peer
Description

GeBBS provides medical coding, RCM, and clinical documentation improvement services to health systems and physician groups, including specialty practices. Comparable as a mid-size RCM/CDI/BPO peer serving specialty providers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

WoundGenex

Healthcare Revenue Cycle Managementwoundgenex.com

WoundGenex provides revenue cycle management, clinical documentation improvement, credentialing, and deferred-payment wound care product distribution to US wound care, podiatry, vascular, and dermatology providers, with specialty focus on Medicare CTP and skin substitute reimbursement.

What WoundGenex does

WoundGenex is a privately held, Tampa, Florida-based healthcare services company founded in 2014 that provides revenue cycle management (RCM), clinical documentation improvement (CDI), and credentialing and enrollment services to wound care providers in the United States. The company is built around wound care specialty billing, with a particular focus on Medicare cellular and tissue-based product (CTP) reimbursement, skin substitute billing, LCD compliance, and denial management. Its technology platform is an online client portal that enables electronic insurance verification requests, product inventory tracking, clinical team communication, and electronic CTP logs; there is no public API, SDK, or AI/ML product capability disclosed in the company's own material.

WoundGenex monetizes through multi-year, quote-based enterprise contracts with healthcare facilities across wound care centers, physician practices, hospitals, surgical centers, nursing homes, and mobile wound care providers, with specialty service lines for podiatry, vascular surgery, and dermatology. In addition to professional services revenue, the company distributes advanced wound care products — including MiMedx placental allografts (EPIFIX, EPICORD, EpiEffect, Celera, Epixpress, RegenKit Wound Gel), UltraMIST therapy, and MolecuLight wound imaging devices — through the Premier Graft Program, a deferred-payment model underpinned by an exclusive distribution partnership with MiMedx Group (Nasdaq: MDXG) established in March 2022.

The company has no disclosed outside funding and appears to be founder-owned, with Thomas Smith serving as President and Co-founder and Tom listed as CEO. In September 2025, WoundGenex formalized a strategic alliance with Shoreline Medical Administration to bundle its RCM platform with Medicare clawback protection backed by an A-rated insurance carrier. The company's go-to-market is direct enterprise field sales supplemented by content marketing on wound care reimbursement policy, credentialing best practices, and regulatory updates published through its corporate website.

WoundGenex firmographics

Firmographics
Name
WoundGenex
Legal name
WoundGenex
Website
https://woundgenex.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
WoundGenex provides revenue cycle management, clinical documentation improvement, credentialing, and deferred-payment wound care product distribution to US wound care, podiatry, vascular, and dermatology providers, with specialty focus on Medicare CTP and skin substitute reimbursement.
Ownership category
akta.pro rank

WoundGenex industry classification

Industry
Product category
Healthcare Revenue Cycle Management
SIC
Services-Health Services (8000)
akta.pro industry
PRIMARYHLAKACAN
Wound Care & Ulcer Management
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLADAJAM
Wound Care & Limb Preservation Centers (Post-Acute)
Healthcare & Life Sciences/Elder Care & Long-Term Care/Rehabilitation & Post-Acute Care Centers (Inpatient/Outpatient)

Keywords

  • Wound care billing
  • Revenue cycle management
  • Clinical documentation improvement
  • Healthcare credentialing services
  • Wound care distribution

Where WoundGenex is headquartered

Location

Headquarters

HQ city
Tampa
HQ country
United States
HQ region
North America

Offices1 record

Markets served

WoundGenex business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Revenue Cycle Management Services: Full-spectrum RCM solutions including claims processing, insurance verification, accounts receivable management, denial management, and billing optimization for wound care practices
  2. Clinical Documentation Improvement Services: CDI services focused on accurate and comprehensive clinical documentation to support proper coding, billing, and compliance
  3. Credentialing & Enrollment Services: Provider enrollment and credentialing management, contract negotiations, and ongoing credential maintenance
  4. Premier Graft Program: Deferred payment model for wound care grafting products where providers pay only after receiving reimbursement, facilitated through group purchasing power with no upfront cost

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom enterprise pricing for healthcare facilities

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

WoundGenex product offering

Product offering

Core offering

WoundGenex provides full-spectrum wound care revenue cycle management (RCM), clinical documentation improvement (CDI), credentialing and enrollment services, and program management for healthcare providers across the United States. The company also distributes advanced wound care products including MiMedx placental allografts (EPIFIX, Epicord, EpiEffect, Celera, Epixpress, RegenKit Wound Gel), UltraMIST therapy, and MolecuLight wound imaging devices, primarily through its Premier Graft Program with a deferred payment model.

Product overview

WoundGenex is a wound care revenue cycle management and practice management solutions company founded in 2014, serving wound care centers, physician practices, nursing homes, and hospitals. The company operates as a distributor of advanced wound care products including MiMedx placental allografts (Epifix, Epicord, EpiEffect, Celera, Epixpress, RegenKit Wound Gel), UltraMIST therapy, and MolecuLight wound imaging devices (MolecuLightDX, MolecuLight i:X). WoundGenex's core offerings include Revenue Cycle Management, Clinical Documentation Improvement, Credentialing & Enrollment, and the Premier Graft Program—a deferred payment model enabling providers to access products with payment due only after reimbursement. The company also provides an online client portal for insurance verification, inventory tracking, and documentation management.

Differentiator

Problem solved

Functional benefit

Products and services

  • Revenue Cycle Management (RCM) Full-spectrum Revenue Cycle Management solutions for wound care practices including eligibility verification, claims submission, insurance correspondence, denial management, accounts receivable management, and reimbursement optimization.
  • Clinical Documentation Improvement (CDI) Clinical Documentation Improvement services ensuring accurate, comprehensive, and compliant clinical documentation in wound care including assessment, analysis, education, training, and technology integration to support proper coding, billing, and audit readiness.
  • Credentialing & Enrollment Provider enrollment and credentialing management services including contract negotiations, ongoing credential maintenance, and ensuring accurate, compliant, and timely submissions to payers.
  • Premier Graft Program Deferred payment program providing healthcare providers access to advanced wound care grafting products (MiMedx allografts) with payment due only after reimbursement is realized, leveraging group purchasing power with no upfront cost to providers.
  • EPIFIX (distributed product) MiMedx advanced wound care placental allograft product used for treating diabetic foot ulcers and other chronic wounds, covered by 100% of national commercial payors.
  • EPICORD (distributed product) MiMedx placental allograft product used for wound care applications.
  • EpiEffect (distributed product) Tri-layer human placental allograft that promotes healing in acute and chronic wounds, combining benefits of human placental tissue with practical application advantages.
  • CELERA (distributed product) MiMedx advanced wound care product for advanced wound management.
  • EPIXPRESS (distributed product) MiMedx wound care placental allograft product for advanced wound management.
  • RegenKit Wound Gel (distributed product) Wound care gel product for advanced wound management applications.
  • UltraMIST (distributed product) Wound care therapy system used in advanced wound treatment.
  • MolecuLightDX (distributed product) Wound imaging device for advanced wound care diagnostics.
  • MolecuLight i:X (distributed product) Wound imaging device for wound care visualization and assessment.

Quantifiable outcome

  • Reduces claim denials through accurate coding and documentation
  • +2 more outcomes

Companies that use WoundGenex

Customer profile

Named customers4 records

Segments6 records

Ideal customer profiles3 records

WoundGenex technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

WoundGenex partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Shoreline Medical AdministrationcoreStrategic or Co-development Partner · 2 September 2025Strategic alliance to deliver bundled revenue cycle solutions with Clawback Protection Guarantee. Shoreline provides rigorous documentation oversight, LCD compliance expertise, and AI validation tools, while WoundGenex provides industry-leading RCM services. The partnership safeguards providers against costly Medicare clawbacks backed by an A-rated insurance carrier.
  • MiMedx Group, Inc.coreChannel Partner/ Reseller/ Distributor · 16 March 2022Exclusive partnership to launch the Premier Graft Program providing MiMedx advanced wound care products (EPIFIX, Epicord, EpiEffect, Celera, Epixpress, RegenKit Wound Gel) through WoundGenex's group purchasing model. Providers access products with no upfront payment until reimbursement is realized.

Scale indicators4 records

Recent moves4 records

Expansion highlights6 records

WoundGenex competitors and assessment

Company assessment

Broad incumbents

  • nThrive: nThrive provides end-to-end revenue cycle management, analytics, and consulting to acute-care and specialty providers. Comparable to WoundGenex as a direct RCM competitor with broader scale and a multi-specialty portfolio.
  • Waystar: Waystar is a healthcare payments and RCM technology platform serving 1M+ providers. Comparable as a tech-enabled claims and revenue cycle vendor, though more horizontal than WoundGenex's wound-care-specialized offering.
  • Parallon: Parallon delivers revenue cycle, credentialing, and workforce solutions to hospitals and physician practices. Comparable as a scaled RCM/credentialing services peer operating across multiple healthcare segments.
  • Conifer Health Solutions: Conifer provides revenue cycle management, patient engagement, and value-based care services for hospitals, health systems, and physician practices. Comparable as an enterprise-scale RCM incumbent with broad service breadth.
  • Experian Health: Experian Health provides patient access, RCM, and identity-management solutions to hospitals and physician practices. Comparable as a large-scale healthcare revenue cycle technology vendor, broader than wound-care-specialized offerings.

Direct peers

  • Wound Care Advantage: Wound Care Advantage offers consulting, program management, and operational support specifically to wound care centers and hyperbaric programs. Closest direct peer given the same wound-care vertical focus on practice optimization and reimbursement.
  • Aviacode (now CorroHealth): Aviacode / CorroHealth offers technology-enabled medical coding and CDI services, including specialty-specific coding for wound care, radiology, and other niches. Comparable as a coding and CDI services peer to WoundGenex's specialty documentation business.
  • Zotec Partners: Zotec Partners delivers specialized revenue cycle management and billing services for physician practices, including niche medical specialties. Comparable as a specialty-focused RCM/BPO peer competing for specialty-practice billing engagements.
  • GeBBS Healthcare Solutions: GeBBS provides medical coding, RCM, and clinical documentation improvement services to health systems and physician groups, including specialty practices. Comparable as a mid-size RCM/CDI/BPO peer serving specialty providers.

Others

  • MiMedx Group: MiMedx is WoundGenex's exclusive Premier Graft Program partner, manufacturer of placental allograft skin substitutes (Epifix, Epicord, EpiEffect, Celera, Epixpress). Relevant as the upstream product vendor rather than a direct competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

WoundGenex social profiles

Digital presence

WoundGenex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

WoundGenex leadership team

Management profile

Number of profiles

Profiles1 record

WoundGenex funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

WoundGenex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WoundGenex

What does WoundGenex do?

WoundGenex provides full-spectrum wound care revenue cycle management (RCM), clinical documentation improvement (CDI), credentialing and enrollment services, and program management for healthcare providers across the United States. The company also distributes advanced wound care products including MiMedx placental allografts (EPIFIX, Epicord, EpiEffect, Celera, Epixpress, RegenKit Wound Gel), UltraMIST therapy, and MolecuLight wound imaging devices, primarily through its Premier Graft Program with a deferred payment model.

Is WoundGenex a public or private company?

WoundGenex is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was WoundGenex founded?

WoundGenex was founded in 2014. It employs 11 to 50 people.

Where is WoundGenex based?

WoundGenex is headquartered in Tampa, United States, in the North America region.

How does WoundGenex make money?

Four revenue lines are on record. Revenue Cycle Management Services are the primary driver. The others are clinical Documentation Improvement Services, credentialing & Enrollment Services and premier Graft Program.

Who are WoundGenex's main competitors?

Broad incumbents on record are nThrive, Waystar, Parallon, Conifer Health Solutions and Experian Health. Direct peers are Wound Care Advantage, Aviacode (now CorroHealth), Zotec Partners and GeBBS Healthcare Solutions. MiMedx Group is listed as an others.

Does WoundGenex have an API?

No public API is recorded for WoundGenex.

What industry is WoundGenex in?

WoundGenex's product category is Healthcare Revenue Cycle Management. Its primary akta.pro industry code is HLAKACAN, Wound Care & Ulcer Management, with a secondary code of HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts). Its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarWoundGenex and Shoreline Medical Administration Form Strategic Alliance to Deliver Bundled Revenue Cycle Solutions with Clawback ProtectionWoundGenex and Shoreline Medical Administration announced a strategic alliance to provide bundled revenue cycle solutions with Shoreline's Clawback Protection Guarantee. The program, backed by an A-rated insurance carrier, combines documentation oversight, LCD compliance, and AI validation to safeguard providers against Medicare clawbacks.YahooWoundGenex and Shoreline Medical Administration Form Strategic Alliance to Deliver Bundled Revenue Cycle Solutions with Clawback ProtectionWoundGenex and Shoreline Medical Administration announced a strategic alliance to provide bundled wound care revenue cycle solutions with Shoreline's Clawback Protection Guarantee. The program, backed by an A-rated insurance carrier, combines documentation review, LCD compliance, and AI validation to safeguard providers against Medicare clawbacks.GlobeNewswireTotal Ancillary Joins Forces with WoundGenexTotal Ancillary and WoundGenex announced an alliance to provide wound care providers with administrative services including revenue cycle management and clinical documentation improvement. The partnership aims to reduce claim denials and improve workflow efficiency, with integration already underway for Total Ancillary's national client base.PR NewswireWoundGenex Partners with MIMEDX to Launch Premier Graft Program to Wound Care Providers NationwideWoundGenex, a leading wound care management and clinical services provider, has announced a strategic partnership with MIMEDX Group, Inc. to launch an exclusive Premier Graft Program offering wound care clinicians access to MIMEDX's advanced allograft products through group purchasing power with no upfront cost to providers. The program, described as first-of-its-kind, defers payment for providers until reimbursement is realized on the product. MIMEDX's flagship wound care product EPIFIX® is covered by 100% of national commercial payors for diabetic foot ulcer treatment, representing over 300 million covered lives.